Literature DB >> 28496745

The Relationship Between Atrial Fibrillation and Chronic Kidney Disease : Epidemiologic and Pathophysiologic Considerations for a Dual Epidemic.

David D McManus1,2, Jane S Saczynski1,2, Jeanine A Ward3, Khushleen Jaggi1, Peter Bourrell1, Chad Darling3, Robert J Goldberg2.   

Abstract

Atrial fibrillation (AF) presently affects over 2 million Americans, and the magnitude and population burden from AF continues to increase concomitant with the aging of the U.S. POPULATION: Chronic kidney disease (CKD) is present in 13% of individuals in the U.S., and the prevalence of CKD is also rapidly increasing. The increasing population burden of CKD and AF will profoundly affect the clinical and public health, since CKD and AF are both associated with lower quality of life, increased hospitalization rates, and a greater risk of heart failure, stroke, and total mortality. AF and CKD often co-exist, each condition predisposes to the other, and the co-occurrence of these disorders worsens prognosis relative to either disease alone. The shared epidemiology of CKD and AF may be explained by the strong pathophysiologic connections between these diseases. In order to promote a better understanding of CKD and AF, we have reviewed their shared epidemiology and pathophysiology and described the natural history of patients affected by both diseases.

Entities:  

Year:  2012        PMID: 28496745      PMCID: PMC5153080          DOI: 10.4022/jafib.442

Source DB:  PubMed          Journal:  J Atr Fibrillation        ISSN: 1941-6911


  118 in total

Review 1.  The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease.

Authors:  Giuseppe Remuzzi; Norberto Perico; Manuel Macia; Piero Ruggenenti
Journal:  Kidney Int Suppl       Date:  2005-12       Impact factor: 10.545

2.  Prognostic significance of a reduced glomerular filtration rate and interaction with microalbuminuria in resistant hypertension: a cohort study.

Authors:  Gil F Salles; Claudia R L Cardoso; Vinicius S Pereira; Roberto Fiszman; Elizabeth S Muxfeldt
Journal:  J Hypertens       Date:  2011-10       Impact factor: 4.844

Review 3.  Epidemiology of atrial fibrillation: a current perspective.

Authors:  Lin Y Chen; Win-Kuang Shen
Journal:  Heart Rhythm       Date:  2006-12-15       Impact factor: 6.343

4.  Close bidirectional relationship between chronic kidney disease and atrial fibrillation: the Niigata preventive medicine study.

Authors:  Hiroshi Watanabe; Toru Watanabe; Shigeru Sasaki; Kojiro Nagai; Dan M Roden; Yoshifusa Aizawa
Journal:  Am Heart J       Date:  2009-10       Impact factor: 4.749

5.  Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates.

Authors:  W B Kannel; P A Wolf; E J Benjamin; D Levy
Journal:  Am J Cardiol       Date:  1998-10-16       Impact factor: 2.778

6.  Atrial fibrillation and morbidity and mortality in a cohort of long-term hemodialysis patients.

Authors:  Simonetta Genovesi; Antonio Vincenti; Emanuela Rossi; Daniela Pogliani; Irene Acquistapace; Andrea Stella; Maria Grazia Valsecchi
Journal:  Am J Kidney Dis       Date:  2008-02       Impact factor: 8.860

Review 7.  Atrial fibrillation in end-stage renal disease.

Authors:  Panagiotis Korantzopoulos; Stelios Kokkoris; Tong Liu; Ioannis Protopsaltis; Guangping Li; John A Goudevenos
Journal:  Pacing Clin Electrophysiol       Date:  2007-11       Impact factor: 1.976

Review 8.  Hypertension in obesity.

Authors:  L Romayne Kurukulasuriya; Sameer Stas; Guido Lastra; Camila Manrique; James R Sowers
Journal:  Endocrinol Metab Clin North Am       Date:  2008-09       Impact factor: 4.741

9.  Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications.

Authors:  W M Feinberg; J L Blackshear; A Laupacis; R Kronmal; R G Hart
Journal:  Arch Intern Med       Date:  1995-03-13

10.  Chronic kidney disease and risk of major cardiovascular disease and non-vascular mortality: prospective population based cohort study.

Authors:  Emanuele Di Angelantonio; Rajiv Chowdhury; Nadeem Sarwar; Thor Aspelund; John Danesh; Vilmundur Gudnason
Journal:  BMJ       Date:  2010-09-30
View more
  6 in total

1.  Chronic kidney disease-induced atrial structural remodeling and atrial fibrillation: more studies on the pathological mechanism are encouraged.

Authors:  Huiliang Qiu; Chunlan Ji; Huanlin Wu; Chuan Zou
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-05-10       Impact factor: 3.000

2.  Prognostic significance of cardiorenal dysfunction within 1 year after atrial fibrillation ablation in patients with systolic dysfunction.

Authors:  Toshiharu Koike; Koichiro Ejima; Shohei Kataoka; Kyoichiro Yazaki; Satoshi Higuchi; Miwa Kanai; Daigo Yagishita; Morio Shoda; Nobuhisa Hagiwara
Journal:  Heart Vessels       Date:  2022-07-25       Impact factor: 1.814

3.  Association between serum alkaline phosphatase and cardiovascular events in patients with atrial fibrillation.

Authors:  Naoharu Yagi; Shinya Suzuki; Takuto Arita; Takayuki Otsuka; Mikio Kishi; Hiroaki Semba; Hiroto Kano; Shunsuke Matsuno; Yuko Kato; Tokuhisa Uejima; Yuji Oikawa; Minoru Matsuhama; Mitsuru Iida; Junji Yajima; Takeshi Yamashita
Journal:  Heart Vessels       Date:  2022-07-29       Impact factor: 1.814

4.  Bidirectional Association Between Kidney Function and Atrial Fibrillation: A Population-Based Cohort Study.

Authors:  Anna C van der Burgh; Sven Geurts; M Arfan Ikram; Ewout J Hoorn; Maryam Kavousi; Layal Chaker
Journal:  J Am Heart Assoc       Date:  2022-05-17       Impact factor: 6.106

Review 5.  Red blood cell distribution width: A marker of anisocytosis potentially associated with atrial fibrillation.

Authors:  Giuseppe Lippi; Gianfranco Cervellin; Fabian Sanchis-Gomar
Journal:  World J Cardiol       Date:  2019-12-26

6.  Association between atrial fibrillation and risk of end-stage renal disease among adults with diabetes mellitus.

Authors:  Yu-Kang Chang; Hueng-Chuen Fan; Chi-Chien Lin; Yuan-Hung Wang; Wan-Ni Tsai; Paik-Seong Lim
Journal:  PLoS One       Date:  2022-08-26       Impact factor: 3.752

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.